Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
FDA regulators today announced landmark approval of a mobile headband-like device indicated for prevention of migraines and migraine pain. The device, called the Cefaly system, is the 1st of its kind and is indicated as an alternative to drug therapy.
The new Cefaly technology is a mobile, non-invasive nerve stimulation system that delivers electrical energy via a plastic band worn across the forehead. The device aims to stimulate the trigeminal nerve, which doctors believe is associated with migraines. Read more
Patient Safety Technologies said it settled several lawsuits brought by shareholders seeking to block its $120 million buyout by Stryker.
The safety-sponge maker agreed in January to the $2.22-per-share acquisition. By Feb. 25 PSTX stock owners had filed 4 lawsuits seeking class-action status in California and Delaware, according to a regulatory filing. Read more
A federal appeals court reconsidered a lawsuit between Medtronic and Boston Scientific in light of the U.S. Supreme Court’s decision this year that Boston Scientific bears the burden of proof concerning a patent it licenses from Mirowski Family Ventures.
In January the Supremes ruled unanimously that MFV must prove that Medtronic’s devices are in violation even though Medtronic filed the original challenge against the patent in 2003, while still under a sub-license agreement for the technology. Read more